ORLANDO, Fla., July 19, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE– Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS announced today that their lead therapy, Lodonal (LDN), was featured in an article published in Plus Magazine: https://www.hivplusmag.com/i-am-warrior/2018/7/12/will-needs-long-term-survivors-be-heard.
Plus Magazine (formally HIVPlus Magazine) was founded in 1998 and is a leading direct to consumer publication providing cutting edge information on HIV research, treatment, prevention and policy. Plus Magazine is distributed in the waiting rooms of AIDS service organization, HIV clinics and HIV specialists across the United States.
“The incidence of GI complication in HIV patients is on the rise exponential to increasing survival rates but still remain unaddressed and contributing to treatment failures and costs of long term management of HIV,” stated Noreen Griffin, Immune Therapeutics CEO.
“The publication in HIV Plus is raising awareness of this clinical disparity that will provoke dialogue at AIDS 2018 on the clinical options, including Lodonal for treating Crohn’s IBS, IBD, UC and C.DIF in studies being considered by investigators in recognized publically supported clinical research networks.”
The article, Will The Needs of Long-Term Survivors Be Heard, published in the July edition of Plus, outlines the need for a concentrated focus by HIV medical and research communities to address the issues of accelerated aging and HIV GI co- morbidities including Crohn’s disease, UC and IBS. HIV co- morbidities are now the leading cause of death among HIV patients. The article suggests that data on LDN strongly supports further studies in HIV by the AIDS Clinical Trials Groups (ACTG’s), a federally funded HIV clinical trials system supported by the National Institute of Allergies and Infectious Diseases (NIAID). Will The Needs of Long-Term Survivors Be Heard sites the study of LDN in Crohn’s patients as well as the data from studies of LDN in HIV patients. The article also mentions an ongoing study (PETERPAIN), which is studying pain in HIV patients. The study, which takes place at Boston Medical Center, is analyzing the effect of low- dose naltrexone, similar to that of LDN, and a second opioid receptor antagonist, Nalmefene on pain.
ABOUT IMMUNE THERAPEUTICS, INC.
Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of our highly innovative immunotherapies. IMUN is a biotechnology company developing T-Activation immunotherapies to achieve immunomodulation in patients with autoimmune and inflammatory disease and cancer and infectious diseases.
Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other chronic infectious diseases.
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.